{"nct_id":"NCT05845814","title":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-09","start_date":"2023-06-23","start_date_type":"ACTUAL","primary_completion_date":"2027-05-31","primary_completion_date_type":"ESTIMATED","completion_date":"2027-05-31","completion_date_type":"ESTIMATED","phases":["PHASE1","PHASE2"],"tickers":["MRK"]}